Avastin, Altuzan ( bevacizumab ) 400 мг, Roche, Gernany
Indication
Treatment of metastatic colorectal cancer:
in combination with chemotherapy based on fluoropyrimidine derivatives.
Treatment of metastatic breast cancer:
first line treatment in combination with paclitaxel;
first-line treatment in combination with capecitabine (when treatment with other chemotherapy regimens, including taxanes or anthracyclines, is considered inappropriate). Avastin® in combination with capecitabine should not be prescribed to patients who have received taxane- and anthracycline-based treatment regimens as adjuvant therapy during the past 12 months.
Treatment of unresectable advanced, metastatic, or recurrent non-small cell lung cancer, except predominantly non-squamous cell lung cancer:
first-line treatment in combination with chemotherapy based on platinum derivatives.
Treatment of advanced unresectable, metastatic or recurrent non-squamous non-small cell lung cancer with EGFR-activating mutations (EGFR — epidermal growth factor receptor) in adult patients:
Treatment of advanced and/or metastatic renal cell carcinoma in adult patients:
the first line of therapy in combination with interferon alfa-2a.
Treatment of advanced (stages IIIB, IIIC and IV according to the classification of the International Federation of Obstetrics and Gynecology (FIGO)) epithelial ovarian cancer, fallopian tube and primary peritoneal cancer in adult patients:
first line therapy in combination with carboplatin and paclitaxel.
Treatment of the first recurrence of epithelial ovarian cancer, fallopian tube and primary peritoneal cancer sensitive to treatment with platinum drugs:
in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel in adult patients who have not received prior therapy with bevacizumab or other VEGF inhibitors or agents that target the VEGF receptor.
Treatment of recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer resistant to treatment with platinum drugs:
in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin in adult patients who have received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or drugs that target the VEGF receptor.
Treatment of persistent, recurrent or metastatic cervical cancer:
in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in adult patients who cannot receive therapy with platinum drugs.
Treatment of recurrent glioblastoma (stage IV according to WHO):
as monotherapy after previous temozolomide therapy.
first-line treatment in combination with erlotinib.
-
Commercial name:Avastin
-
Сhemical name:Bevacizumab
-
Dosage:400 mg
-
Quantity:one
-
Release form:Флакон, концентрат
-
Производитель:Roche, Германия